Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:PFE
Pfizer Inc (PFE)
26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
Financials 
Technical Analysis 0
PAST TOP PICK
The stock has increased since he picked it. They have raised their dividends. It has a high yield. He continues to own.
Norman LevineOwned
biotechnologypharmaceutical
TOP PICK
Good value for a bounce. Expects another 15/20% upside. Treating it as a Trade, not for the long term.
Ross HealyOwned
biotechnologypharmaceutical
BUY
Likes it and still buying for new clients. Have a pipeline of new drugs and using their cash to develop new drugs. Have sold their consumer products division. Have increased their dividends and doing buybacks.
Norman LevineOwned
biotechnologypharmaceutical
SELL
TOP PICK
A defensive position. Very cheap. Lots of value and seems to have momentum.
Ross HealyOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 10/06. No change.) A large cap stock that is going into transition. Sold their consumer products area. Wants to see how this affects the balance sheet. 4% dividend. Still likes.
Brian Acker, CAOwned
biotechnologypharmaceutical
BUY
All the major drug stocks are starting to act better. In the state of market, money moves from risky stocks to defensive stocks. Has a great yield. A good place to be.
Norman LevineOwned
biotechnologypharmaceutical
TOP PICK
It has a model price of $33.93 which is a 42% positive differential. Have now sold their consumer division and their balance sheet is going to be a lot smaller. You get the same earnings, but with a smaller balance sheet, which creates, value.
Brian Acker, CAOwned
biotechnologypharmaceutical
TOP PICK
Have cleared their problems with Cellebrex. Selling their consumers product division for $16 billion cash. This will probably go to share repurchase, increased dividends and acquisition of promising drugs from small companies. Cheap.
Norman LevineOwned
biotechnologypharmaceutical
BUY
A real defensive story. Have tremendous internal cash flow. Have a sound dividend and they buy back stocks. A real value play. New drugs coming out are really solid.
Paul Gardner, CFAOwned
biotechnologypharmaceutical
BUY
Got rid of a lot of their past problems. The whole drug sector has been a difficult place to be because of pricing pressures, lawsuits, etc. The worst is now over. Large pharmaceuticals are international, so as the US$ drops, their foreign assets increase.
Norman LevineOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
